BR112012019868A2 - composição farmacêutica para uso tópico - Google Patents
composição farmacêutica para uso tópicoInfo
- Publication number
- BR112012019868A2 BR112012019868A2 BR112012019868-8A BR112012019868A BR112012019868A2 BR 112012019868 A2 BR112012019868 A2 BR 112012019868A2 BR 112012019868 A BR112012019868 A BR 112012019868A BR 112012019868 A2 BR112012019868 A2 BR 112012019868A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- topical use
- oligonucleotides
- asdnas
- sirens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
Abstract
composição farmacêutica para uso tópico. a presente invenção refere-se a uma composição cosmética e/ou dermatológica e/ou farmacêutica para uso tópico e aplicação de oligonucleotídeos, particularmente oligonucleotídeos anti-sentido, como dnazimas, sirnas, asdnas ou ribozimas, para uso como agentes contra doenças inflamatórias, por meio de emulsões com fase aquosa dispersa, interna, descontínua.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010007562.0 | 2010-02-10 | ||
DE102010007562A DE102010007562A1 (de) | 2010-02-10 | 2010-02-10 | Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide |
PCT/EP2011/000648 WO2011098285A2 (de) | 2010-02-10 | 2011-02-11 | Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012019868A2 true BR112012019868A2 (pt) | 2018-07-31 |
BR112012019868B1 BR112012019868B1 (pt) | 2021-06-08 |
Family
ID=43899573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012019868-8A BR112012019868B1 (pt) | 2010-02-10 | 2011-02-11 | composição farmacêutica para uso tópico |
Country Status (8)
Country | Link |
---|---|
US (2) | US9249413B2 (pt) |
EP (1) | EP2533763B1 (pt) |
JP (1) | JP5896921B2 (pt) |
BR (1) | BR112012019868B1 (pt) |
CA (2) | CA2827049C (pt) |
DE (1) | DE102010007562A1 (pt) |
RU (1) | RU2570378C9 (pt) |
WO (1) | WO2011098285A2 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010007562A1 (de) | 2010-02-10 | 2011-08-11 | sterna biologicals GmbH & Co KG, 35043 | Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide |
ES2753436T3 (es) * | 2015-05-15 | 2020-04-08 | Sterna Biologicals Gmbh & Co Kg | Inhibidores de GATA-3 para su uso en el tratamiento del asma mediada por Th2 |
WO2017205506A1 (en) * | 2016-05-24 | 2017-11-30 | Emory University | Particles with rna cleaving nucleobase polymers and uses for managing inflammatory disorders |
GB201700257D0 (en) * | 2017-01-06 | 2017-02-22 | Atlantic Pharmaceuticals (Holdings) Ltd | New formulation |
EP3805242A1 (en) * | 2019-10-07 | 2021-04-14 | Sterna Biologicals GmbH & Co. KG | Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma |
US11976282B2 (en) | 2020-06-23 | 2024-05-07 | Qatar University | GATA3 inhibitors for the promotion of subcutaneous fat deposition |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6841539B1 (en) | 1998-05-21 | 2005-01-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
WO2000009673A1 (en) * | 1998-08-13 | 2000-02-24 | Johnson & Johnson Research Pty. Limited | Dnazymes and methods for treating hpv-related disorders |
DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
DK1562968T3 (da) | 2001-11-14 | 2013-10-28 | Janssen Biotech Inc | Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
DE10238298A1 (de) | 2002-08-21 | 2004-03-04 | Beiersdorf Ag | Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen |
DE10254214A1 (de) | 2002-11-20 | 2004-06-09 | Beiersdorf Ag | Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz |
DE10346487A1 (de) | 2003-10-02 | 2005-05-12 | Transmit Technologietransfer | Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels |
DE102004010547A1 (de) | 2004-03-03 | 2005-11-17 | Beiersdorf Ag | Oligoribonukleotide zur Behandlung von irritativen und/oder entzündlichen Hauterscheinungen durch RNA-Interferenz |
US20090209623A1 (en) | 2005-07-25 | 2009-08-20 | Jon Tomono | Anti-sense nucleic acid derived from organism |
FR2890074B1 (fr) | 2005-09-01 | 2007-11-23 | Lvmh Rech | Nouveaux oligonucleotides anti-genes specifiques de la tyrosinase comme agents depigmentants |
DE102007020554A1 (de) | 2007-04-27 | 2008-10-30 | Henkel Ag & Co. Kgaa | Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes |
DE102010007562A1 (de) | 2010-02-10 | 2011-08-11 | sterna biologicals GmbH & Co KG, 35043 | Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide |
-
2010
- 2010-02-10 DE DE102010007562A patent/DE102010007562A1/de not_active Ceased
-
2011
- 2011-02-11 WO PCT/EP2011/000648 patent/WO2011098285A2/de active Application Filing
- 2011-02-11 CA CA2827049A patent/CA2827049C/en active Active
- 2011-02-11 JP JP2012552313A patent/JP5896921B2/ja active Active
- 2011-02-11 EP EP11705444.5A patent/EP2533763B1/de active Active
- 2011-02-11 CA CA2996580A patent/CA2996580C/en active Active
- 2011-02-11 BR BR112012019868-8A patent/BR112012019868B1/pt active IP Right Grant
- 2011-02-11 RU RU2012137904/15A patent/RU2570378C9/ru active
- 2011-02-11 US US13/578,013 patent/US9249413B2/en active Active
-
2015
- 2015-12-10 US US14/965,371 patent/US9404110B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2827049A1 (en) | 2011-08-18 |
JP2013527134A (ja) | 2013-06-27 |
US20130030038A1 (en) | 2013-01-31 |
DE102010007562A1 (de) | 2011-08-11 |
US9404110B2 (en) | 2016-08-02 |
US20160115478A1 (en) | 2016-04-28 |
CA2996580C (en) | 2020-06-30 |
JP5896921B2 (ja) | 2016-03-30 |
BR112012019868B1 (pt) | 2021-06-08 |
EP2533763A2 (de) | 2012-12-19 |
CA2996580A1 (en) | 2011-08-18 |
RU2570378C9 (ru) | 2016-03-10 |
EP2533763C0 (de) | 2023-07-12 |
WO2011098285A3 (de) | 2012-04-19 |
CA2827049C (en) | 2019-08-13 |
RU2012137904A (ru) | 2014-03-20 |
WO2011098285A8 (de) | 2011-12-29 |
US9249413B2 (en) | 2016-02-02 |
EP2533763B1 (de) | 2023-07-12 |
WO2011098285A2 (de) | 2011-08-18 |
RU2570378C2 (ru) | 2015-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012019868A2 (pt) | composição farmacêutica para uso tópico | |
BRPI0918139A2 (pt) | composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso | |
UY33396A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
BR112013011868A2 (pt) | compostos de pirimidina hidróxi amida como inibidores da proteína desacetilase, composição farmacêutica e uso dos referidos compostos | |
CR20130259A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
BR112014016649A2 (pt) | composições para tratamento dos cabelos | |
CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
CL2013001138A1 (es) | Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición. | |
BR112015010772A2 (pt) | composição de enxágue tópica, uso de uma composição e método para tratar ou melhorar a pele de um indivíduo contra a acne | |
BR112015004747A2 (pt) | moléculas oligonucleotídicas de fita dupla para p53 e métodos de uso das mesmas | |
CL2013002123A1 (es) | Composicion herbicida que comprende topramezona y pinoxaden; uso de dicha composicion para controlar vegetación indeseable; formulación indeseable. | |
CL2011002835A1 (es) | Compuestos derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para tratar dolores agudos o cronicos de tipos neurogeno, asociados a enfermedades inflamatorias, entre otros. | |
BR112014010174A2 (pt) | uso de uma composição para a fabricação de um produto para melhorar a função executiva de um indivíduo e para tratar o mesmo | |
ES2543957T3 (es) | Nueva composición farmacéutica para el tratamiento de infecciones fúngicas | |
BR112013022556A8 (pt) | composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol | |
BR112015009892A2 (pt) | Anticorpo contra il-1 beta, seu método de produção e seu uso, sequência isolada de ácido nucleico, vetor, composição cosmética, de diagnóstico ou farmacêutica, e kit | |
BR112013004829A2 (pt) | composição de agente de dispersão de produto químico agrícola, composição química agrícola, método para produzir um produto agrícola, método para aumentar eficácia em um produto químico agrícola, e uso da composição de agente de dispersão de produto químico agrícola. | |
BR112014000139A2 (pt) | formulação para cuidado pessoal, uso do composto ativo, composto ativo, e, método de reduzir atrito na superfície da fibra capilar | |
BR112015004613A2 (pt) | agonistas para o receptor trpm-8; combinações de substâncias ativas de agonistas; preparações cosméticas ou dermatológicas contendo um ou mais agonistas de trpm-8, um ou mais polióis, e uma ou mais substâncias de ação antieritematosa ou inibidora de inflamação | |
WO2012104240A3 (de) | Kosmetische verwendung | |
BR112013000779A2 (pt) | composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial | |
BR112014011481A2 (pt) | hidrolisado de colágeno e seu uso | |
BR112015014885A2 (pt) | combinação de agentes ativos, composição cosmética e/ou dermatológica e processo para a preparação de uma composição de agentes ativos. | |
BR112015006692A2 (pt) | formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: STERNA BIOLOGICALS GMBH AND CO. KG (DE) |
|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/02/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |